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Abstract We recently reported that glucosamine reversed the
decrease in proteoglycan synthesis and in UDP-glucuronosyl-
transferase I mRNA expression induced by interleukin-1L (IL-
1L) [Arthritis Rheum. 44 (2001) 351^360]. In the present work,
we show that glucosamine does not exert the same effects when
chondrocytes were stimulated with reactive oxygen species
(ROS). In order to better understand its mechanism of action,
we determined if glucosamine could prevent the binding of IL-1L
to its cellular receptors or could interfere with its signaling
pathway at a post-receptor level. Addition of glucosamine to rat
chondrocytes treated with IL-1L or with ROS decreased the
activation of the nuclear factor UB, but not the activator
protein-1. After treatment with IL-1L, glucosamine increased the
expression of mRNA encoding the type II IL-1L receptor. These
results emphasize the potential role of two regulating proteins of
the IL-1L signaling pathway that could account for the beneficial
effect of glucosamine in osteoarthritis. ß 2002 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Osteoarthritis (OA) is characterized by cartilage alterations,
such as quantitative and qualitative modi¢cations of proteo-
glycans (PGs) and collagens. An imbalance between the bio-
synthesis and the degradation of matrix components leads to
a progressive destruction of the tissue, resulting in extensive
articular damage [1]. Cartilage damage in OA is known to be
largely mediated by interleukin 1L (IL-1L), a cytokine that
initiates a number of events leading to cartilage destruction,
including the inhibition of matrix macromolecule biosynthesis
and the increase of catabolic pathways.
IL-1L stimulates the transcription of many genes through
the activation of di¡erent transcription factors such as nuclear
factor UB (NF-UB) or activator protein-1 (AP-1). NF-UB
binding sites are present in the promoter regions of many
genes involved in the pathophysiology of joint in£ammation
and tissue destruction [2]. IL-1 binds to the IL-1 receptor type
I (IL-1RI) that activates tumor necrosis factor receptor mol-
ecule-associated factor-6 (TRAF-6), leading to the activation
of NF-UB-inducing kinase (NIK) [3]. In this way, NF-UB can
enter the nucleus and activate target genes by binding with
high a⁄nity to UB response elements. Alternatively, TRAF-6
can also activate mitogen-activated protein kinase (MAPK).
The MAPK pathways promote phosphorylation of other sub-
strates, such as c-Jun N-terminal kinase and the Jun and Fos
family, all of which are associated with a transcriptional ac-
tivity of AP-1 [3].
Some symptomatic slow-acting drugs, such as glucosamine
[4], have been shown to be e¡ective in relieving the symptoms
of OA. Reports of symptomatic relief a¡orded by glucosam-
ine on the treatment of OA have spurred new research into its
mechanism of action on cartilage [4^6]. In this respect, we
have previously shown that glucosamine (4.5 g/l) prevented
the IL-1L-mediated decrease in PG synthesis. This process
was related, in part, to a decrease in the expression of
UDP-glucuronosyltransferase I (GlcAT-I), which is involved
in the biosynthesis of glycosaminoglycans. Glucosamine was
also suggested in the literature to act through the scavenging
of free radicals [7,8]. However, this way of action has never
been proved. We only showed in a previous work that glucos-
amine modulated the expression of in£ammatory enzymes (in-
ducible NO synthase) and the production of NO [9].
Since IL-1L treatment is well known to lead to the produc-
tion of reactive oxygen species (ROS) by cells, we hypothe-
sized that glucosamine could prevent the action of IL-1L by
antioxidant e¡ects. Secondly, we wanted to know if the amino
sugar could prevent the binding of IL-1L to its cell surface
receptors, or could interfere at post-receptor levels. Therefore,
the objectives of this study were (i) to look for a potential
antioxidant e¡ect of glucosamine by incubating chondrocytes
with a ROS-generating system and comparing the results with
those obtained in IL-1L-stimulated cells, (ii) to determine if
glucosamine could modulate the binding of IL-1 on its recep-
tor via a possible increase in type II IL-1 receptor (IL-1RII)
which is a decoy receptor, or an increase in IL-1 receptor
antagonist (IL-1ra), and (iii) to examine the possible e¡ects
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of glucosamine on the activation of two nuclear factors, NF-
UB and AP-1.
2. Materials and methods
2.1. Chemicals
D-(+)-Glucosamine and D-(+)-glucose were supplied by Sigma Chi-
mie (St Quentin Fallavier, France). Dulbecco’s modi¢ed Eagle’s me-
dium (DMEM), fetal calf serum (FCS), L-glutamine, gentamicin, re-
verse transcriptase, and restriction enzymes were obtained from
Gibco-BRL (Cergy Pontoise, France). Taq polymerase was supplied
by Eurobio (Les Ulis, France), and the nucleotides were synthesized
by MWG-Biotech (Ebersberg, Germany). Recombinant human IL-1L
was purchased from Pepro-Tech (Tebu, Le Perray en Yveline,
France).
2.2. Chondrocyte cultures and treatments
Male Wistar rats (130^150 g) (Charles River, Saint-Aubin-le's-El-
bEuf, France) were housed under controlled temperature and lighting
conditions with food and water ad libitum. Articular cartilage, iso-
lated from femoral head caps, was aseptically dissected, and chondro-
cytes were obtained after digestion of the cartilage fragments in pro-
nase (2% w/v in 0.15 M NaCl) followed by an overnight digestion in
collagenase B (1.5% w/v in DMEM without serum) [10]. The experi-
ments were performed with ¢rst-passage cultures, 6 days after colla-
genase treatment. For this purpose, chondrocytes were grown to con-
£uence for 6 days in 25-cm2 £asks (about 4U106 chondrocytes per
£ask) in 5 ml of complete medium (DMEM supplemented with 2 mM
L-glutamine, 50 Wg/ml gentamicin, 10% FCS v/v). Cells were then
cultured for 6 h in FCS-free medium containing glucose (4.5 g/l) or
glucosamine (4.5 g/l), and ¢nally stimulated with IL-1L (25 or 250
U/ml) for 16 h.
For stimulation with a ROS-generating system, cells were incubated
for 30 min in a glucose- or glucosamine-containing medium in the
presence of hypoxanthine (4 mM) and xanthine oxidase (10 mU/ml)
[11]. Cells were then cultured in glucose- or glucosamine-containing
medium for 8 h (mRNA expression determination) or for 16 h (PG
synthesis measurement). For the determination of proteoglycan syn-
thesis, chondrocytes were entrapped into alginate beads as follows.
The cells were suspended in sterile ¢ltered low viscosity alginate so-
lution (1.2% w/v) at 6U106 cells/ml and slowly expressed through a
22-gauge needle into a 100 mM CaCl2 solution. After two washes
with 0.15 M NaCl, beads were cultured for 6 days in complete me-
dium containing 4.5 g/l of glucose. Before stimulation with ROS or
IL-1L, cells were cultured with complete medium with 2% FCS, for 8 h
in the presence of 4.5 g/l of glucose or glucosamine.
2.3. Measurement of PG biosynthesis
The incorporation of radiolabeled sodium sulfate into PGs in rat
chondrocytes encapsulated into alginate beads was measured 16 h
after ROS or IL-1L stimulation. Alginate beads were incubated in
complete medium (4.5 g/l glucose or glucosamine) containing 2%
FCS and supplemented with 10 WCi/ml of Na2 35SO4 for 4 h at
37‡C. The encapsulated chondrocytes were washed several times
with 0.15 M NaCl and solubilized in Soluene 350 (0.5 M quaternary
ammonium hydroxide in toluene) overnight. The amount of radio-
labeled sulfate incorporated, considered a reliable evaluation of the
amount of newly synthesized sulfated glycosaminoglycans [12,13], was
quanti¢ed by liquid scintillation.
2.4. Analysis of GlcAT-I, and IL-1RII mRNA expression by
quantitative reverse transcriptase polymerase chain reaction
(RT-PCR)
Total RNA was isolated from cell cultures by a single-step guani-
dinium thiocyanate^phenol chloroform method using Trizol (Life
Technologies) according to the manufacturer’s protocol. mRNA ex-
pression by rat chondrocytes was analyzed using a quantitative multi-
standard RT-PCR, a method that takes advantage of sequence con-
servation of both the gene of interest and L-actin between animals
species [14]. The protocol allowed us to normalize the amount of
mRNA of the gene of interest with respect to that of L-actin
mRNA in each sample. Total RNA samples extracted from rat cells
were mixed with a constant amount of RNA prepared from mouse
tissues, which brought the sequences of both competitive mouse L-ac-
tin and the gene of interest and thus acted as a multistandard source.
For ampli¢cation of GlcAT-I, the direct primer extended from nucle-
otide 267 to 290 and the reverse primer from nucleotide 592 to 619, in
accordance with the rat sequence (GenBank accession number
AB009598). Each ampli¢cation product was distinguished by restric-
tion site polymorphism: BamHI digested the mouse GlcAT-I ampli-
¢cation product into two fragments (121 and 304 bp), while the rat
product remained uncut.
For ampli¢cation of IL-1RII, the direct primer extended from nu-
cleotides 401 to 421, and the reverse primer extended from nucleotides
723 to 744 in accordance with the rat sequence (GenBank accession
number Z22812). EcoRI digested the mouse IL-1RII product into
2 fragments (228 and 115 bp), while the rat product remained uncut.
Digested RT-PCR products were resolved by agarose gel electro-
phoresis stained with ethidium bromide. The bands were visualized
under UV light and photographed by a computer-assisted camera.
Quantitation of each band was performed by densitometry analysis
with NIH software. Results are expressed as the ratio (analyzed
generat/L-actinrat)U(L-actinmouse/analyzed genemouse), in arbitrary
units.
2.5. Preparation of nuclear extracts
The nuclear extracts were prepared from rat chondrocytes as de-
scribed in detail before [15]. Brie£y, cell monolayers were washed in
ice-cold phosphate-bu¡ered saline and scraped in 1 ml of bu¡er A (10
mM HEPES, pH 7.9, 10 mM KCl, 1 mM dithiothreitol) containing a
protease inhibitor cocktail (Boehringer Mannheim) and 0.5% Igepal
(Sigma). Cell extracts were incubated for 15 min on ice, with inter-
mittent mixing. Nuclei were collected by centrifugation at 1500Ug for
5 min at 4‡C. The nuclear pellets were washed with 1 ml of bu¡er A
without Igepal and resuspended in 50 Wl of bu¡er B (10 mM HEPES,
pH 7.9, 420 mM NaCl, 1 mM dithiothreitol) containing the same
protease inhibitor cocktail. The tubes were mixed thoroughly and
incubated for 30 min on ice. Nuclear debris were removed by centri-
fugation at 13 000Ug for 10 min at 4‡C. The supernatants were col-
lected and stored at 380‡C before use. The protein content was de-
termined according to the method of Bradford [16].
2.6. Electrophoretic mobility shift assay (EMSA)
The DNA sequences of the double-stranded oligonucleotide speci¢c
for NF-UB were 5P-GAT CCA GTT GAG GGG ACT TTC CCA
GGC G-3P and 5P-GAT CCG CCT GGG AAA GTC CCC TCA
ACT G-3P. Those speci¢c for AP-1 were 5P-GAT CCG CTT GAT
GAC TCA GCC GGA AG-3P and 5P-GAT CCT TCC GGC TGA
GTC ATC AAG CG-3P. Complementary strands were annealed, and
double-stranded oligonucleotides were labeled with [32P]dCTP using
the Klenow fragment of DNA polymerase (Life Technologies). Nu-
clear extracts (5 Wg of protein) were incubated for 10 min at 4‡C in a
total volume of 20 Wl containing 2 Wg of poly(dI-dC) and 2 Wl of
10Ugel shift binding bu¡er (20 mM Tris^HCl, pH 7.9, 5 mM MgCl2,
0.5 mM dithiothreitol, 0.5 mM EDTA, and 20% glycerol). The ex-
tracts were then incubated for 30 min at 4‡C with 10 000 cpm of
32P-labeled NF-UB or AP-1 probes (MWG-Biotech). The samples
were loaded on a 5% native polyacrylamide gel, and run in
0.5UTBE bu¡er. The gel was dried and subjected to autoradiography.
NF-UB- and AP-1-speci¢c bands were con¢rmed by competition with
a 100-fold excess of an unlabeled NF-UB or AP-1 probe, which re-
sulted in no shifted band.
2.7. Statistical analysis
After comparison of data by analysis of variance, the di¡erent
groups were compared using Fisher’s t-test. Assays were made in
triplicate. P values less than 0.05 were considered signi¢cant.
3. Results
3.1. Glucosamine prevents the IL-1L-induced changes on both
GlcAT-I mRNA expression and PG synthesis, but not after
ROS stimulation.
Since IL-1 and tumor necrosis factor have been reported to
increase ROS in chondrocytes [17], thus decreasing the bio-
synthesis of PG, we hypothesized that glucosamine could re-
verse both the ROS and the IL-1L e¡ects. For this reason, the
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concentration of the hypoxanthine/xanthine oxidase system
(4 mM, 10 mU/ml) was chosen to produce approximately
similar reductions of PG synthesis and GlcAT-I mRNA ex-
pression to those produced by 250 U/ml IL-1L treatment. To
investigate the e¡ects of glucosamine on ROS-mediated or IL-
1L-mediated PG synthesis decrease, rat chondrocytes were
isolated, maintained in culture in the presence of glucose or
glucosamine and challenged with ROS or IL-1L. Treatment of
chondrocytes with ROS or IL-1L in glucose medium resulted
in a signi¢cant decrease in both GlcAT-I mRNA expression
(343% for ROS and 351% for IL-1L, P6 0.05; Fig. 1) and
PG synthesis (322% for ROS and 324% for IL-1L, P6 0.05;
Fig. 2). However, in contrast to what we observed with IL-1L
treatment, addition of glucosamine provided less signi¢cant
prevention against the ROS-mediated inhibitory e¡ects on
GlcAT-I mRNA expression (331%, P6 0.05; Fig. 1) and
on PG synthesis (327.5%, P6 0.05; Fig. 2). Moreover, sim-
ilarly to previous data [9], glucosamine induced a PG synthe-
sis decrease by itself (338%, P6 0.05; Fig. 2), but had no
e¡ect on GlcAT-I mRNA expression (Fig. 1). The present
results ¢rstly show that glucosamine was able to counteract
the inhibition of expression of GlcAT-I mRNA. Secondly,
glucosamine was only able to counteract the further inhibition
of PG synthesis caused by IL-1L treatment but not after ROS
challenge. The decrease in PG synthesis induced by ROS pro-
duction could be related to di¡erent cellular pathways than
those involved in the IL-1L challenge.
3.2. IL-1L induced an increase in the expression of
IL-1RII mRNA in the presence of glucosamine
We therefore investigated the in£uence of glucosamine on
the mRNA expression of the decoy receptor IL-1RII in chon-
drocytes treated or not with IL-1L. The addition of IL-1L (25
U/ml or 250 U/ml) for 12 h to a culture medium containing
glucose did not induce any variation of IL-1RII mRNA ex-
pression (Fig. 3). On the other hand, the IL-1L-mediated stim-
ulation of cultured rat chondrocytes in the presence of glu-
cosamine led to a dose-dependent increase in the expression of
this mRNA, reaching 51% at the higher dose of the cytokine
(Fig. 3). No signi¢cant di¡erence was observed between con-
trols containing glucose and glucosamine, in the absence of
IL-1L. We also evaluated the e¡ects of IL-1L on IL-1ra
mRNA expression. In contrast to IL-1RII, no variation in
IL-1ra mRNA expression was measured in the presence of
glucosamine (data not shown).
3.3. Glucosamine inhibits the NF-UB but not the
AP-1 signaling pathway
In order to investigate the in£uence of glucosamine on IL-
1L-mediated e¡ects in rat chondrocytes, we further examined
the activation of two transcriptional pathways of the in£am-
matory response, i.e. NF-UB and AP-1. As expected, treat-
Fig. 1. E¡ect of ROS or IL-1L on GlcAT-I mRNA expression in
rat chondrocytes cultured in the presence of glucose (white bars) or
glucosamine (gray bars). Cells were cultured for 6 h in serum-free
medium containing glucose or glucosamine before being incubated
for 30 min in the same medium in the presence of hypoxanthine
(4 mM) and xanthine oxidase (10 mU/ml). mRNA expressions were
quanti¢ed as described in Section 2. Lane 1: glucose medium; lane
2: glucose+IL-1L (250 U/ml); lane 3: glucose+ROS; lane 4: glucos-
amine medium; lane 5: glucosamine+IL-1L (250 U/ml); lane 6: glu-
cosamine+ROS. Results are expressed in relative arbitrary units,
and are the mean þ S.D. of three di¡erent assays (n = 3; *P6 0.05
versus respective control).
Fig. 2. E¡ect of ROS or IL-1L on PG synthesis in rat chondrocytes
cultured in the presence of glucose (white bars) or glucosamine
(gray bars). Cells were cultured in alginate beads in 2% FCS me-
dium containing glucose (4.5 g/l) or glucosamine (4.5 g/l). ROS
were produced as reported in the legend of Fig. 1, and 16 h later,
radiolabeled sulfate incorporation was analyzed as described in Sec-
tion 2. Lane 1: glucose medium; lane 2: glucose+IL-1L (250 U/ml);
lane 3: glucose+ROS; lane 4: glucosamine medium; lane 5: gluco-
samine+IL-1L (250 U/ml); lane 6: glucosamine+ROS. Results are
expressed as percentage of variations by comparison to the control
(value of 100 for glucose medium) and are the mean þ S.D. of three
di¡erent assays (n = 3; *P6 0.05 versus respective control, #P6 0.05
versus 4.5 g/l glucose medium).
Fig. 3. E¡ect of IL-1L treatment on IL-1RII mRNA expression in
rat chondrocytes in the presence of glucose (white bars) or glucos-
amine (gray bars). Cells were cultured for 6 h in FCS-free medium
containing glucose (4.5 g/l) or glucosamine (4.5 g/l), and ¢nally
stimulated with IL-1-L (25 U/ml or 250 U/ml) for 16 h. Lane 1:
glucose medium; lane 2: glucose+25 U/ml IL-1L ; lane 3: glu-
cose+250 U/ml IL-1L ; lane 4: glucosamine medium; lane 5: glucos-
amine+25 U/ml IL-1L ; lane 6: glucosamine+250 U/ml IL-1L. Re-
sults are expressed in relative arbitrary units, and are the
mean þ S.D. of three di¡erent assays (n = 3; *P6 0.05 versus respec-
tive control).
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ments of chondrocytes in glucose-containing medium by IL-
1L or ROS induced the activation of both NF-UB (Fig. 4A)
and AP-1 (Fig. 4B). However, the NF-UB activation induced
by ROS was shown to be lower than that induced by IL-1L.
The presence of glucosamine instead of glucose in the culture
medium did not modulate the activation of AP-1 induced by
IL-1L or ROS treatments. In contrast and interestingly, the
presence of glucosamine in the medium signi¢cantly reduced
NF-UB activation induced by IL-1L and inhibited that in-
duced by ROS (Fig. 4A).
4. Discussion
OA a¡ects approximately 12% of the population, and the
incidence increases with age. Current treatments for OA are
limited to short-term symptom control with acetaminophen
and non-steroidal anti-in£ammatory drugs, which do not
slow or reverse the degenerative process. Glucosamine has
recently received a great deal of attention from the public as
a potential treatment for OA [4,5] since this drug has been
proposed to slow down and possibly reverse these degenera-
tive processes [18]. However, the mechanisms of the bene¢cial
e¡ect of glucosamine on cartilage disease are still unknown. In
a recent study, we have demonstrated that glucosamine at a
dose of 4.5 g/l reversed the IL-1L-mediated e¡ects on enzymes
such as GlcAT-I and MMP-3 in rat chondrocytes in culture.
We also showed that glucosamine not only corrected these
e¡ects but also antagonized the production of various pro-
in£ammatory mediators activated by IL-1L, such as NO and
prostaglandin E2 [9]. Altogether, these results suggested that
the pharmacological e¡ects of glucosamine in the treatment of
OA would involve a modulating action of this amino sugar at
some stages of IL-1 signaling events.
There are many potential ways in which glucosamine could,
directly or indirectly, modify IL-1 signaling pathways. The
protective e¡ects of glucosamine have been considered at
three separate levels : (i) towards the e¡ects induced by radi-
cals, (ii) the variations of mRNA encoding the expression of
the decoy receptor IL-1RII and the receptor antagonist IL-
1ra, and (iii) the activation of two transcriptional nuclear
factors, NF-UB and AP-1, known to be involved in in£amma-
tion. IL-1 induces a cellular stress that can generate ROS
production, which, in turn, could activate the NF-UB pathway
by interacting with NIK [19]. We hypothesized that the pres-
ence of ROS could explain the decrease in PG synthesis. If
glucosamine reversed the IL-1-mediated decrease in PG syn-
thesis, no e¡ect was observed on ROS-mediated variations in
either GlcAT-I mRNA expression or biosynthesis of PG.
These data suggest that ROS and IL-1 decreased the PG syn-
thesis via two di¡erent pathways.
Two types of IL-1 receptors have been described. The in-
£ammatory e¡ect of IL-1 requires signaling through the cyto-
plasmic domain of IL-1RI. The decoy IL-1RII can also inter-
act with IL-1. However, as a truncated protein, its interaction
with the cytokine is unable to generate signaling. By trapping
part of IL-1, the decoy receptor can modulate its concentra-
tion and e¡ects. This property makes IL-1RII a potential
target in order to block the IL-1L signaling pathways [20].
Many studies suggest that IL-1RII plays an important phys-
iological role in the regulation of IL-1 action in the in£am-
mation sites [21]. Several drugs, such as aspirin or glucocorti-
costeroids, could induce this decoy receptor, thus decreasing
in£ammation by preventing the binding of IL-1L to target
cells [22,23]. Our study showed that the mRNA expression
of IL-1RII was not changed in rat chondrocytes challenged
with IL-1L in the presence of glucose. However, the expres-
sion of the decoy receptor was signi¢cantly increased in chon-
drocytes cultured in the presence of glucosamine, but only
when the cells were treated with IL-1L. By increasing IL-
1RII mRNA expression, glucosamine is able to reduce the
binding of IL-1L on IL-1RI and therefore modulates its ef-
fects. However, at this state of the work, we are unable to
explain by which mechanism glucosamine induces the increase
in IL-1RII expression in IL-1L-treated chondrocytes.
When IL-1L binds to IL-1R, the signal is transmitted within
the cell through a cascade of signaling proteins that can be
potential targets of glucosamine. The results presented in this
study show that glucosamine signi¢cantly decreases the e⁄-
ciency of the IL-1L signaling pathway by antagonizing NF-UB
activation. Several compounds, such as phenylarsine, the anti-
Fig. 4. E¡ect of glucosamine on NF-UB (A) or AP-1 (B) activation
mediated by IL-1L or ROS. Chondrocyte cultures were treated with
IL-1L (250 U/ml for 1 h) or ROS (30 min) as described in Section
2. Nuclear proteins were extracted and 5 Wg of each sample was
subjected to EMSA using NF-UB or AP-1 consensus site radiola-
beled probes. Lane 1: radiolabeled probe alone; lane 2: 100U con-
centrated unlabeled probe; lane 3: glucose control; lane 4: glucos-
amine control; lane 5: glucose+250 U/ml IL-1L ; lane 6:
glucosamine+250 U/ml IL-1L ; lane 7: glucose+ROS; lane 8: gluco-
samine+ROS. Band intensities were quanti¢ed with densitometry
analysis software (NIH image). The experiments were performed
three times; representative results are shown.
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oxidant quercetin or the non-steroidal anti-in£ammatory drug
tepoxalin, have been described to inhibit the translocation of
NF-UB into the nucleus [24^26]. Our results showed that glu-
cosamine had no signi¢cant e¡ect on IL-1L-mediated AP-1
activation. Thus, these data would suggest that glucosamine
acts downstream of TRAF-6 in the IL-1L signaling pathways
[3]. Moreover, we found that glucosamine also blocked the
activation of NF-UB induced by ROS, whereas it was inactive
on PG synthesis and GlcAT-I mRNA expression. This result
shows that the blocking of the NF-UB activation pathway is
not su⁄cient or is not involved in the restoration of proteo-
glycan synthesis. Induction of cyclooxygenase 2 and inducible
NO synthase by in£ammatory cytokines is known to be partly
mediated by NF-UB [27^29]. Therefore, the anti-in£ammatory
e¡ects of glucosamine on the production of prostaglandin E2
and NO [9] could be explained, at least in part, via an inhi-
bition of the binding of NF-UB to its response elements.
Moreover, most MMP genes are characterized by the presence
of an AP-1 binding site in their proximal promoter that me-
diates transcriptional activation by growth factor, phorbol
ester and oncogenes [30]. For the expression of MMP-3, the
transcription factor AP-1 is essential (but not su⁄cient) for
the upregulation of this enzyme under pro-in£ammatory cy-
tokines; NF-UB activity is also involved in MMP-3 up-regu-
lation [31]. Hence, the bene¢cial e¡ects of glucosamine can be
explained, at least in part, by the inhibition of NF-UB tran-
scriptional activity.
In conclusion, the present work demonstrates that glucos-
amine acts, at least, at two di¡erent levels in rat chondrocytes
(NF-UB activation and IL-1RII expression). Thus, these re-
sults contribute to clarify the mechanisms of action of glucos-
amine on cartilage.
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